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Abstract
Aims/hypothesis The aim of this study was to study dynam-
ic changes in the prevalence of different types of diabetes in
paediatric populations in Poland, with a specific focus on
monogenic diabetes (MD).
Methods Using epidemiologic data (PolPeDiab Collabora-
tion) and nationwide genetic test results (TEAM Programme),
we compared the prevalence of type 1, type 2 and cystic
fibrosis-related diabetes (CFRD) and MD. Genetically
confirmed MD included MODY, neonatal diabetes and
Wolfram and Alström syndromes. The study covered all
children aged 0–18 years treated for diabetes between
2005 and 2011 in three regions, inhabited by 23.7%
(1,989,988) of Polish children, with a low prevalence
of childhood obesity (<5%).
Results The prevalence of type 1 diabetes showed a contin-
uous increase, from 96 to 138/100,000 children. The prev-
alence of type 2 diabetes and CFRD also increased, from 0.3
to 1.01/100,000 children and from 0.1 to 0.95/100,000
children, respectively. The prevalence of MD was stable at
between 4.2 and 4.6/100,000 children, accounting for 3.1–
4.2% of children with diabetes, with glucokinase (GCK)-
MODY being the most frequent type, amounting to 83% of
patients with MD. The percentage of positive test results
decreased with the number of referrals, suggesting that
children with the highest probability of MD were referred
initially, followed by those with a less clear-cut phenotype.
The prevalence of neonatal diabetes equalled 1 in 300,000
children.
Conclusions/interpretation The prevalence of MD in a pae-
diatric population with a low prevalence of obesity remains
stable and is nearly fivefold higher than that of type 2
diabetes and CFRD, justifying a need for increased access
to genetic diagnostic procedures in diabetic children.
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Introduction
The literature reports a wide range of prevalence of
monogenic diabetes (MD), making it difficult to perform
economic analyses and estimate the feasibility of genetic
screening procedures [1–3]. Efforts to estimate the prev-
alence of paediatric type 2 diabetes mellitus are similarly
challenging, there being a wide range of estimated values
[1, 2]. To improve on this situation, we report here
accurate prevalence estimates of different types of child-
hood diabetes based on extensive epidemiological and
genetic data from three major academic paediatric diabe-
tes clinics [4, 5].
Methods
The study aimed to estimate the prevalence and relative
frequency of type 1, type 2 and other specific types of
diabetes (according to the ADA classification) in children
of a European country with a low prevalence of overweight
and obesity [6]. The diagnosis of MD was defined to cover
the following genetic diagnoses with at least one confirmed
case amongst Polish children in the period between January
2005 and December 2011: MODY, persistent neonatal dia-
betes mellitus and Wolfram and Alström syndromes. This
study protocol was approved by the Bioethics Committee of
the Medical University of Lodz. Guardians of all study
participants gave informed consent.
Epidemiological data were obtained from the publicly
available online database of the Central Statistical Office
of Poland (www.stat.gov.pl/bdlen/app/strona.html?p_ name-
indeks, accessed 5 January 2012). The paediatric population
covered by the study constituted 23.7% of children in
Poland. To assure the uniformity of data, only patients aged
0–18 years with diabetes entered the analysis.
Classification of the type of diabetes in patients covered
by this analysis was based on a joint expert opinion of the
diabetologists at the respective centres. Uniform recruitment
criteria for MODY described by Ellard et al were adopted in
2008 by all participating centres [7]. Clinical characteristics
used before that date are described in the electronic supple-
mentary material (ESM Methods 1). Children with a suspi-
cion of neonatal diabetes entered genetic screening if their
diabetes manifested during the initial 6 months of life.
Phenotypic characteristics suggestive of Wolfram or
Alström syndromes were evaluated by the attending
diabetologist and verified by members of the research team
within the principal study centre in Lodz. The diagnostic
criteria for type 2 diabetes were based on OGTT, the ab-
sence of signs of diabetic ketoacidosis at diagnosis, obesity
(>2 SD-BMI), a high level of endogenous insulin produc-
tion assessed by fasting C-peptide level, marked insulin
resistance, detection of acanthosis nigricans, a family history
of diabetes and obesity and, if possible to ascertain, the
absence of autoantibodies.
The primary method used in screening for genetic defects
causative for diabetes was DNA sequencing performed us-
ing fluorescent-labelled terminating deoxynucleoside tri-
phosphates with gene-specific oligonucleotide primers, and
multiplex ligation-dependent probe amplification was used
Fig. 1 (a) Increase of referral rate throughout the study period. The
lower area (dark grey) represents patients with positive genetic test
results for any kind of MD. The upper area (light grey) represents
children referred for genetic testing and with negative genetic test
results. GCK-MODY was the most commonly observed form, detected
in 83% of children referred for genetic screening, followed by neonatal
diabetes (7%), HNF1A/HNF4A-MODY (4%), HNF1B-MODY (2%)
and diabetes in Wolfram and Alström syndromes (2% and 1%, respec-
tively). (b) Number of children with type 1 diabetes (T1DM, circles),
type 2 diabetes (T2DM, diamonds), monogenic diabetes (MD, squares)
and CFRD (triangles) treated at the three study centres throughout the
study region. Owing to the rapidly increasing number of children with
type 1 diabetes, the percentage of diabetic patients with MD relative to
the overall population of diabetic children decreased from 4.1% in
2005 to 3.2% in 2011, while the percentages of type 1 diabetes, type 2
diabetes and CFRD all increased. The left hand axis depicts the number of
children with type 1 diabetes, while the right hand axis shows the number
of children with monogenic or type 2 diabetes or CFRD
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for detecting exon deletions (MRC-Holland, Amsterdam,
the Netherlands). Details of the molecular methods are
provided in ESM Methods 2. Prevalence calculations were
performed for all four analysed types of diabetes: type 1,
type 2, monogenic and cystic fibrosis (CF)-related diabetes
(CFRD). A p value lower than 0.05 was considered statisti-
cally significant.
Results
Throughout the study period the number of children with
diabetes in the studied voivodeships (major administrative
regions of Poland) increased from 2,008 to 2,568, whereas
the total number of children decreased linearly, resulting in a
net reduction of more than 200,000 (ESM Table 1). During
the period of analysis, 1,351 individuals from 597 families
were referred for genetic tests from 28 hospitals and clinics
throughout the entire country. Of that number, 311 children
(23.01%) from 238 families originated from the three voi-
vodeships, with the largest number of referrals and complete
epidemiological data for type 1 diabetes. Children were
referred for genetic testing on a suspicion of: GCK-MODY
(n0259) (involving the gene encoding glucokinase [GCK]),
HNF1A/HNF4A-MODY (n028) and HNF1B-MODY (n04)
(involving genes encoding hepatocyte nuclear factor
[HNF]), neonatal diabetes due to KCNJ11, ABCC8, GCK
or INS mutations (n015), Wolfram syndrome (n03),
Alström syndrome (n01) or an unspecified syndrome of
neonatal diabetes with congenital heart defect and cytoge-
netic abnormalities (n01). A pathogenic mutation was
confirmed in 100 cases (details on the accuracy of specific
genetic diagnoses are presented in ESM Results). The over-
all accuracy of clinical diagnosis, defined as the percentage
of positive genetic confirmations of suspected MD, was
32.15% (range 25.55–44.00%). The number of children
referred to genetic studies showed a steady, linear increase
throughout the study period (Pearson’s r00.893; p00.017),
but the percentage of positive genetic tests decreased with
the number of referred patients (Fig. 1a). The group of
patients with positively confirmed MD was greater than
those with newly diagnosed type 2 diabetes or CFRD
(Fig. 1b and Table 1). Prevalence calculations confirmed
earlier findings of an increase in the number of patients
with type 1 diabetes. The prevalence of type 2 diabetes
increased from 0.3/100,000 to 1.0/100,000 children—these
values were, respectively, 13.9 and 4.3 times lower than the
prevalence of MD in the study group, which equalled
4.2–4.6/100,000 children. The final prevalence of neonatal
diabetes due to KCNJ11 or ABCC8 mutations was
1/300,000–400,000 children, yielding a number similar
to an earlier collaborative epidemiological report [8].
Discussion
Results of the current study confirm our clinical observa-
tions that MD is a much more common phenomenon than
paediatric type 2 diabetes in settings with low frequencies of
obesity. We observed that the prevalence of MD differed
considerably from earlier reports, probably because of pro-
tocol differences and unrestricted access to genetic studies








Number of new type 2 diabetes diagnoses 3 8 14 25
Number of new CFRD diagnoses 4 10 4 15
Number of MD diagnoses
MODY 26 35 29 90
GCK 25 32 27 84
HNF1A/4A 1 3 0 4
Other 0 0 2 2
Neonatal diabetes 3 1 3 7
WFS and ALMS 2 and 1 0 0 3
Median delay between diagnosis of diabetes
and genetic testing (25–75%) (years)
1.27 (0.21–4.65) 0.80 (0.16–1.64) 0.73 (0.22–2.39) 0.84 (0.19–2.70)
Median age of patients with MD at genetic
examination (25–75%) (years)
10.10 (3.12–16.21) 10.86 (7.33–17.55) 13.79 (6.21–16.89) 11.05 (6.65–16.56)
Duration of the delay between the diagnosis of diabetes and referral for genetic tests did not differ between study centres, probands or siblings, nor
between patients with positive and negative genetic test results, and was not correlated with the year of the study (all p values >0.2 in Mann–
Whitney U test)
ALMS, Alström syndrome; WFS, Wolfram syndrome
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provided by our project. Understandably, if such access is
not readily available, the discrepancy between observed and
actual prevalence is vast. A good example is a recent sur-
veillance study in Canada, which showed a prevalence of
type 2 diabetes similar to that in our study (1.5/100,000
children) but differed considerably in that of MD, by report-
ing a value 20 times lower than in our population (0.2/
100,000 children) [2]. Studies focused on adult patients
unequivocally show that HNF1A/HNF4A-MODY is two to
four times more frequent than GCK-MODY, which is more
prevalent in children and adolescents [3, 9]. This discrepan-
cy results from a difference between the stable clinical
course of GCK-MODY and progressive loss of beta cell
function in MODY types caused by mutations in transcrip-
tion factor genes [10]. Moreover, the delay between onset of
diabetes and genetic confirmation was probably shorter than
in the adult population, further contributing to the over-
representation of GCK-MODY (Table 1). However, if one
considers that GCK-MODY constitutes a proportion of
MODY convergent with studies on adults (~20–50% [7]),
then the prevalence of genetic defects causative for MD in
the whole Polish population would ultimately exceed 1 in
10,000, which agrees with the estimate by Shields et al (108/
1,000,000) [3]. As referral of patients to genetic tests for
MD is generally based on clinical grounds, the apparent
non-linear relationship between the number of referrals
and percentage of subsequent genetic confirmations of the
clinical diagnosis suggests that children with the highest
probability of MD were referred initially, followed by those
with a less clear-cut phenotype. Obviously, this does not
undermine the importance of searching for children with
unusual clinical presentations of diabetes, but it does show
a high potential for other, yet undefined genetic defects,
which we were unable to detect using available methods.
The rise in prevalence of CFRD observed over the
study period could be a result of improved care of
children with CF, increased awareness of its diabetogenic
potential (more frequent OGTT) and reduced mortality
[11]. Unfortunately, because of the lack of centralised or
region-specific databases of children with CF, we were
unable to provide detailed prevalence and annual incidence
characteristics for CFRD with regard to the whole group of
children with CF.
Throughout the whole study period MD was more fre-
quent than both type 2 diabetes and CFRD. The prevalence
of type 2 diabetes was lower than that reported in countries
with higher rates of overweight and obesity [1, 2]. In the
Polish population, epidemiological reports on the matter
estimate that between 1.9% and 5.0% of children meet the
criteria for childhood obesity [6]. The prevalences of
MODY and type 2 diabetes in German children were
reported to be almost equal [1]. However, as obesity in
German children was 1.7 times more prevalent than in
Poland [6], it may have been a major driving factor altering
the MODY/type 2 diabetes ratio in the paediatric popula-
tion. One might, however, suspect that the prevalence of
type 2 diabetes was underestimated because of the fluid
distinction between type 1 and type 2 diabetes, coupled with
an increasing rate of childhood obesity. Surprisingly, despite
the fact that 20% of patients from the Lodz centre underwent
examination using hyperinsulinaemic–euglycaemic clamp
testing to measure insulin resistance, the observed number
of cases with type 2 diabetes was the lowest among the three
centres. This may result from regional discrepancies but also
from an over-representation of type 2 diabetes in children
without access to more sophisticated examination proce-
dures that would allow the diabetologist to rule out the
insulin resistance component in a patient with an ambiguous
diagnosis.
Conclusions
The prevalence of MD in a paediatric population with a low
prevalence of obesity is nearly fivefold higher than those of
type 2 diabetes and CFRD, justifying a need for increased
access to genetic diagnostic procedures in diabetic children.
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